StoxDr. Reddy's Laboratories vs Mankind Pharma: share price & financials comparison
NSE: DRREDDY vs MANKIND · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Reddy's Laboratories vs Mankind Pharma at a glance
Dr. Reddy's Laboratories (DRREDDY) has a market capitalisation of ₹1,14,646 Cr, against ₹1,04,902 Cr for Mankind Pharma (MANKIND). Over the past year Dr. Reddy's Laboratories has returned +9.8%, compared with +3.9% for Mankind Pharma. On valuation, Dr. Reddy's Laboratories trades at a lower P/E of 40.9 versus 46.7. Mankind Pharma earns a higher return on equity (12.8% vs 7.2%). Dr. Reddy's Laboratories comes out ahead on size, valuation, financial health, momentum and technicals. Mankind Pharma comes out ahead on profitability and growth. Across the scored metrics below, Dr. Reddy's Laboratories leads on 9 and Mankind Pharma on 7. On StoxGud's 10-point checklist, Dr. Reddy's Laboratories scores 5/10 and Mankind Pharma scores 7/10.
| Metric | Dr. Reddy's Laboratories | Mankind Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,14,646 Cr | ₹1,04,902 Cr |
| Revenue (latest FY) | ₹33,700 Cr | ₹14,278 Cr |
| Net profit (latest FY) | ₹4,196 Cr | ₹1,913 Cr |
| Valuation | ||
| P/E | 40.9 | 46.7 |
| P/B | 2.95 | 5.97 |
| Dividend yield | 0.58% | 0.04% |
| Profitability | ||
| Return on equity | 7.2% | 12.8% |
| Net profit margin | 8.5% | 14.6% |
| Operating margin | 14.7% | 26.5% |
| Growth | ||
| Revenue growth (YoY) | -1.5% | +17.3% |
| Net profit growth (YoY) | -31.3% | +39.1% |
| Revenue CAGR (multi-year) | +12.1% | +17.7% |
| Financial health | ||
| Debt to equity | 0.15 | 0.31 |
| Momentum | ||
| 1-month return | +14.1% | +1.6% |
| 1-year return | +9.8% | +3.9% |
| 3-year CAGR | +8.7% | +13.0% |
| 5-year CAGR | +7.5% | — |
| 10-year CAGR | +8.3% | — |
| Distance from 52W high | -0.2% | -3.0% |
| Technicals | ||
| RSI (14) | 84 | 72 |
| Price vs 200-day avg | +9.9% | +9.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Reddy's Laboratories | Mankind Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 5/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Reddy's Laboratories or Mankind Pharma?
Dr. Reddy's Laboratories has a market cap of ₹1,14,646 Cr and Mankind Pharma has a market cap of ₹1,04,902 Cr as of 06 Nov 2026.
Which has a lower P/E, Dr. Reddy's Laboratories or Mankind Pharma?
Dr. Reddy's Laboratories has the lower P/E: Dr. Reddy's Laboratories trades at 40.9 and Mankind Pharma at 46.7.
Which gave better returns in the last year, Dr. Reddy's Laboratories or Mankind Pharma?
Dr. Reddy's Laboratories did better: Dr. Reddy's Laboratories returned +9.8% and Mankind Pharma returned +3.9% over one year.
Is Dr. Reddy's Laboratories or Mankind Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Reddy's Laboratories scores 5/10 and Mankind Pharma scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.